Kyinsu

Kyinsu is a once-weekly, fixed-dose injectable combination drug developed by Novo Nordisk for the treatment of type 2 diabetes mellitus in adults. It contains two active substances: insulin icodec, a long-acting basal insulin analogue that regulates glucose metabolism by binding to insulin receptors, and semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that modulates insulin and glucagon secretion in a glucose-dependent manner. Delivered via a prefilled pen, Kyinsu is indicated as an adjunct to diet, exercise, and oral antidiabetic medications for patients whose glycemic control is insufficiently managed with basal insulin or GLP-1 receptor agonist therapy alone. The combination has been approved in South Korea and Brazil, and authorized in the European Union, supported by the Phase III COMBINE clinical trial program.

Brand names

Kyinsu诺和杰

Other names

IcoSemainsulin icodec + semaglutideinsulin icodec/semaglutide